United States Bi-Specific Monoclonal Antibodies (Bi-Specific MAbs) Market 2025: Industry Developments, Future Growth, Share & Industry Insights

The Global Bi-Specific Monoclonal Antibodies (Bi-Specific MAbs) Market size increased from US$ 4.82 billion in 2023 to US$ 5.51 billion in 2024 and is projected to reach US$ 15.43 billion by 2033, growing at a CAGR of 15.4% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Bi-Specific MAbS Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/bi-specific-mabs-market?sg

Key Players: Amgen, Genentech / Roche, Genmab, Janssen Biotech and Immunocore Limited.

USA - Industry Latest News:

✅ Jul 02, 2025 - Regeneron: LynozyficTM (linvoseltamab-gcpt) - FDA accelerated approval for relapsed/refractory multiple myeloma (BCMA × CD3 T-cell engager).
(Clinical impact: first-line competition in later-line myeloma space; immediate commercialization in US.)

✅ Jun 02, 2025 - Bristol-Myers Squibb / BioNTech (deal affects US commercial rights): BMS agreed to co-develop / co-commercialize BioNTech's PD-L1×VEGF-A bispecific candidate BNT327 (deal with large upfront and milestone structure worldwide program). This is a major industry partnership (effectively a multi-billion-dollar strategic play into bispecific oncology in the US/global market).

Japan - Industry Latest News:

✅ Mar 19, 2025 - Chugai Pharmaceuticals: Launched LUNSUMIO (intravenous formulation) - a CD20×CD3 T-cell-engaging bispecific antibody, for certain B-cell lymphomas; local commercial launch/availability announced in Japan.

✅ Jun 23, 2025 - Otsuka / Harbour BioMed collaboration news: Announced HBM7020 (BCMA×CD3 bispecific) - novel T-cell engager candidate and relevant Phase-stage disclosure/press release in Japan (development progress / company update).

South Korea - Industry Latest News:

✅ Jun 24 - Jul 07, 2025 - ABL Bio (Seoul) (partnered with I-Mab): clinical data / presentations for Givastomig / ABL111 (Claudin-18.2 × 4-1BB bispecific) - new Phase 1b combination data announced / selected for oral presentation at ESMO GI 2025; ABL emphasized global development (rights/partnership structure: ABL retains certain country rights). This is a Korea-based developer advancing bispecifics through clinic and seeking global positioning.

Europe - Industry Latest News:

✅ Jun 02, 2025 - BioNTech (Germany) & Bristol-Myers Squibb (US/Global): strategic global co-development & co-commercialization agreement for BNT327 (PD-L1×VEGF-A bispecific) - headline multi-billion USD collaboration that anchors European biotech presence in the bispecific oncology race.

Growth Forecast Projected:

The Global Bi-Specific MAbS Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Bi-Specific MAbS Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bi-specific-mabs-market?sg

Key Segments:

By Type (Catumaxomab, Blinatumomab, Duligotumab, Others)

By End User ( Research Institutes, Hospitals, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Bi-Specific MAbS producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Bi-Specific MAbS revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/bi-specific-mabs-market?sg

FAQ's

Q1: What is the current size of the Bi-Specific MAbS Market?

A: The Bi-Specific MAbS Market stood at US$ 5.51 billion in 2024 and is set to experience remarkable growth, reaching US$ 15.43 billion by 2033

Q2: How fast is the Bi-Specific MAbS Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 15.4% from 2025-2033

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/bi-specific-mabs-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.